Full Text:   <796>

CLC number: 

On-line Access: 2015-03-05

Received: 2014-07-05

Revision Accepted: 2014-12-02

Crosschecked: 2015-02-18

Cited: 0

Clicked: 1871

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Viroj Wiwanitkit

http://orcid.org/0000-0003-1039-3728

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2015 Vol.16 No.3 P.251-252

10.1631/jzus.B1500035


Non-specific anti-viral approach towards Ebola virus infection: a comment on “Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis”


Author(s):  Beuy Joob, Viroj Wiwanitkit

Affiliation(s):  Sanitation 1 Medical Academic Center, Bangkok 10160, Thailand; more

Corresponding email(s):   wviroj@yahoo.com

Key Words:  Ebola, Non-specific anti-viral


Share this article to: More <<< Previous Article|

Beuy Joob, Viroj Wiwanitkit. Non-specific anti-viral approach towards Ebola virus infection: a comment on “Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis”[J]. Journal of Zhejiang University Science B, 2015, 16(3): 251-252.

@article{title="Non-specific anti-viral approach towards Ebola virus infection: a comment on “Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis”",
author="Beuy Joob, Viroj Wiwanitkit",
journal="Journal of Zhejiang University Science B",
volume="16",
number="3",
pages="251-252",
year="2015",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1500035"
}

%0 Journal Article
%T Non-specific anti-viral approach towards Ebola virus infection: a comment on “Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis”
%A Beuy Joob
%A Viroj Wiwanitkit
%J Journal of Zhejiang University SCIENCE B
%V 16
%N 3
%P 251-252
%@ 1673-1581
%D 2015
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1500035

TY - JOUR
T1 - Non-specific anti-viral approach towards Ebola virus infection: a comment on “Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis”
A1 - Beuy Joob
A1 - Viroj Wiwanitkit
J0 - Journal of Zhejiang University Science B
VL - 16
IS - 3
SP - 251
EP - 252
%@ 1673-1581
Y1 - 2015
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1500035


Abstract: 
The recent "Viewpoint" by Zhang et al. (2015) entitled "Against ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis", pub-lished in Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), is very interesting, which mentioned the possible role of non-specific anti-viral approach towards ebola virus infection. They noted the role of interferon and "applying a non-specific anti-viral approach during the incubation period of virus infection as an essential protection to put the host's immune system into an alert state and henceforth to slow down the viral replication." In previous report, Zhang and Wang (2014) mentioned the long history of ebola virus infection discovery. However, the success in disease management is still not reached. Indeed, the role of interferon in treatment of ebola has been widely discussed (Shuchman, 2014). The effectiveness of interferon has been proved in some animal models (Smith et al., 2013).

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Anderson, G., Maes, M., Markus, R.P., et al., 2015. Ebola virus: melatonin as a readily available treatment option. J. Med. Virol., 87(4):537-543.

[2]Eickmann, M., Schumacher, B., 2014. Therapeutic use of immune sera. Ebola survivors as lifesavers? MMW Fortschr. Med., 156(19):6 (in German).

[3]Mentré, F., Taburet, A.M., Guedj, J., et al., 2015. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect. Dis., 15(2):150-151.

[4]Nagata, T., Lefor, A.K., Hasegawa, M., et al., 2014. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med. Public Health Prep., 29:1-3.

[5]Oestereich, L., Lüdtke, A., Wurr, S., et al., 2014. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res., 105:17-21.

[6]Rager-Zisman, B., 2014. Antibody therapy to limit the spread of Ebola virus. Isr. Med. Assoc. J., 16(12):743.

[7]Shuchman, M., 2014. Could interferon help treat Ebola? CMAJ, 186(16):1204.

[8]Smith, L.M., Hensley, L.E., Geisbert, T.W., et al., 2013. Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis., 208(2):310-318.

[9]Tan, D.X., Korkmaz, A., Reiter, R.J., et al., 2014. Ebola virus disease: potential use of melatonin as a treatment. J. Pineal Res., 57(4):381-384.

[10]Zhang, L., Wang, H., 2014. Forty years of the war against Ebola. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(9):761-765.

[11]Zhang, L., Wang, H., Zhang, Y.Q., 2015. Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 16(1):1-9.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE